Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Reporting Entity

v3.19.3
Note 1 - Reporting Entity
9 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1.
Reporting entity:
 
Aptose Biosciences Inc. (“Aptose” or the “Company”) is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company’s executive offices are located in San Diego, California and its head office is located in Toronto, Canada.
 
Aptose has
two
clinical-stage programs and a
second
program that is discovery-stage and partnered with another company.
CG026806
(“CG-
806”
), Aptose’s pan-FMS-like tyrosine kinase
3
/ pan-Bruton’s tyrosine kinase inhibitor, is currently enrolling patients in a Phase
1a/b,
multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-
806
in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). Aptose plans to seek allowance from the FDA to move into patient populations that include relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in a separate Phase
1
trial. APTO-
253,
Aptose’s
second
program, is a small molecule MYC inhibitor and is currently enrolling patients in a Phase
1b
clinical trial for the treatment of patients with R/R blood cancers, including AML and high-risk Myelodysplastic Syndrome.